A G Harris
Overview
Explore the profile of A G Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
1354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan M, OSullivan M, Faitli B, Mellerio J, Fawkes R, Wood M, et al.
Br J Dermatol
. 2020 Feb;
182(3):e89-e114.
PMID: 32107777
Epidermolysis bullosa (EB) is a complex rare condition that affects the skin and many parts of the body. Those born with EB have skin so fragile they are called 'butterfly...
2.
Khan M, OSullivan M, Faitli B, Mellerio J, Fawkes R, Wood M, et al.
Br J Dermatol
. 2019 Aug;
182(3):593-604.
PMID: 31397882
This guideline was designed to provide service providers and users with an evidence-based set of current best practice guidelines for people and their families and carers, living with epidermolysis bullosa...
3.
Miller P, Hattersley G, Lau E, Fitzpatrick L, Harris A, Williams G, et al.
Bone
. 2018 Oct;
120:137-140.
PMID: 30359763
Background: Abaloparatide is a 34-amino acid peptide that selectively binds to the RG conformation of the parathyroid hormone receptor type 1. It was developed for the treatment of women with...
4.
Bilezikian J, Hattersley G, Fitzpatrick L, Harris A, Shevroja E, Banks K, et al.
Osteoporos Int
. 2017 Nov;
29(2):323-328.
PMID: 29167971
Introduction: Subcutaneous abaloparatide (abaloparatide-SC) increases total hip and lumbar spine bone mineral density and reduces vertebral and non-vertebral fractures. In this study, we analyzed the extent to which abaloparatide-SC improves...
5.
Zhao C, Wijayanti A, Doria M, Harris A, Jain S, Legaspi K, et al.
Int J Womens Dermatol
. 2017 May;
1(3):150-154.
PMID: 28491979
Background: Outcome measures for atopic dermatitis (AD) patients with pigmented skin have neither been developed nor validated. Objective: To compare the reliability and validity of four common AD outcome measures...
6.
Jain S, Harris A, Su J, Orchard D, Warren L, McManus H, et al.
J Eur Acad Dermatol Venereol
. 2016 Sep;
31(4):692-698.
PMID: 27580431
Background: The lack of validated outcome measures for epidermolysis bullosa (EB) presents major barriers to evaluating disease severity and comparing the efficacy of therapies. The Epidermolysis Bullosa Disease Activity and...
7.
Harris A, Choy C, Pigors M, Kelsell D, Murrell D
Br J Dermatol
. 2016 May;
174(5):1160-1.
PMID: 27206363
No abstract available.
8.
Wang Y, Tache Y, Harris A, Kreutner W, Daly A, Wei J
Allergy
. 2004 Dec;
60(1):117-24.
PMID: 15575942
Background: Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. Desloratadine inhibits the release of allergic inflammatory mediators in vitro. We studied the...
9.
Bousquet J, Boushey H, Busse W, Canonica G, Durham S, Irvin C, et al.
Clin Exp Allergy
. 2004 Jun;
34(6):897-903.
PMID: 15196277
Background: Allergic rhinitis and asthma often co-exist and appear to produce a continuum of airway disease, but whether the clinical characteristics of asthma in patients with seasonal rhinitis differ from...
10.
Harris A, Schropp A, Messmer K
Langenbecks Arch Chir Suppl Kongressbd
. 2003 Oct;
115(Suppl I):447-51.
PMID: 14518294
The present data indicate that treatment with Oxaceprol results in a significant protection of the microvasculature against I/R injury. The infusion of Oxaceprol during reperfusion leads to a significant reduction...